Skyrizi Subcutaneous Injection 75mg Syringe 0.83mL, manufactured by AbbVie, contains Risankizumab (genetical recombination) (YJ code: 3999450G1028, 75mg 0.83mL tube). This IL-23 inhibitor is used for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis in adults.
Skyrizi Subcutaneous Injection 75mg Syringe 0.83mL
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).